wikidoc - User contributions [en]

Chronic obstructive pulmonary disease epidemiology and demographics

2014-06-12T14:04:05Z

Hilda Mahmoudi:

__NOTOC__
{{Chronic obstructive pulmonary disease}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com], {{Hilda}}
==Overview==
COPD occurs in 34 out of 1000 greater than 65 years old. In England, an estimated 842,100 of 50 million people have a diagnosis of COPD; translating into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas. In the United States, the [[prevalence]] of COPD is approximately 1 in 20 or 5%, totalling approximately 13.5 million people in USA,<ref>[http://www.wrongdiagnosis.com/c/copd/prevalence.htm wrongdiagnosis.com > Prevalence and Incidence of COPD] Retrieved on Mars 14, 2010</ref> or possibly approximately 25 million people if undiagnosed cases are included.<ref>[http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf MORBIDITY & MORTALITY: 2009 CHART BOOK ON CARDIOVASCULAR, LUNG, AND BLOOD DISEASES] National Heart, Lung, and Blood Institute</ref>

==Epidemiology and Demographics==
===Developed Countries===
====USA====

=====Mortality=====

* During 2000--2005, COPD was the underlying cause of death for 718,077 persons overall aged >25 years in the United States. The number of deaths from COPD increased from 116,494 in 2000 to 121,267 in 2003, decreased to 117,134 in 2004, and increased to 126,005 in 2005.
* To update national estimates of deaths from COPD for the period 2000-2005 (the most recent years for which data are available), CDC analyzed data from the National Vital Statistics System (NVSS). Results of that analysis indicated that an estimated 126,005 deaths of persons aged >25 years occurred in 2005 with COPD as the underlying cause, an increase of 8% from 116,494 deaths in 2000.
* In 2005, approximately one in 20 deaths in the United States had [[COPD]] as the underlying cause.
* Smoking is estimated to be responsible for at least 75% of COPD deaths.

=====Age=====

* Age-standardized COPD mortality rates remained fairly stable during the period (2000-2005) overall. Age-standardized death rates per 100,000 population decreased during 2000--2004; the rate in 2005 was similar to that for 2003.

=====Race=====

* For each year during 2000--2005, COPD mortality rates were higher among whites than among blacks or persons of all other races. During this period, the rate for blacks remained stable, except for 2004, when the rate was lower. In 2005, the death rate among white men was 80.2 (95% confidence interval [CI] = 79.5--80.9) compared with 63.8 (CI = 61.8--65.8) among black men, 60.3 (CI = 59.8--60.8) among white women, and 29.9 (CI = 28.9--30.9) among black women.

=====Gender=====

* From 2000 to 2005, the annual number of deaths from COPD increased 5% among men, and the number of deaths was higher in 2005 than in 2004. The death rate for men declined during 2000--2005 and was lower in 2004 than in 2005. Among women, the annual number of deaths increased 11% from 2000 to 2005 and was lower in 2005 than in 2004. The death rate for women increased from 2000 to 2003, decreased in 2004, and increased in 2005. The death rate was higher for men compared with the rate for women in each year, but the number of deaths was greater for women. For women, the number of deaths related to COPD in 2005 was 65,193, while for men it was 60,812.

=====Economical Impact=====

* The total economic costs of COPD in the United States were estimated to be $49.9 billion in 2010, and the total direct cost of medical care is approximately $29.5 billion per year.<ref>[A Q, J WT, E WS, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of internal medicine 2011;155:179-91]</ref> Excess health-care expenditures are estimated at nearly $6,000 annually for every COPD patient in the United States.

=====States Based Statistics=====

* By state, in 2005, age-standardized death rates from COPD for adults aged >25 years ranged from 27.1 per 100,000 in Hawaii to 93.6 per 100,000 population in Oklahoma. States with COPD death rates in the highest quartile were as follows: Idaho, Indiana, Kansas, Kentucky, Maine, Montana, Nevada, Ohio, Oklahoma, Vermont, West Virginia, and Wyoming. Among adults aged 25--64 years, rates ranged from 6.2 (Massachusetts and New Jersey) to 19.2 (Oklahoma) per 100,000 population for men and from 3.8 (New Jersey) to 16.5 (West Virginia) in women. Among adults aged >65 years, rates ranged from 169.0 (Hawaii) to 540.4 (Vermont) per 100,000 population in men and from 94.7 (Hawaii) to 394.9 (Nevada) in women.

===Statistics===
====Work Related Lung Disease (World) Surveillance System====
This CDC national surveillance system is maintained by the National Institute for Occupational Safety and Health (NIOSH) and includes up-to-date summary tables, graphs, and figures of occupationally-related respiratory disease surveillance data on the pneumoconioses, occupational asthma and other airways diseases, and several other respiratory conditions including chronic obstructive pulmonary disease. Information is available at http://www2a.cdc.gov/drds/WorldReportData/.

http://www.cdc.gov/copd/images/copd_graph.jpg

===Prevalence in the United States===

http://www.cdc.gov/copd/images/copd_map.png

Age-standardized death rates for chronic obstructive pulmonary disease (COPD), by state, aggregated over 1999–2006. State rates are grouped into quartiles. Data were obtained from the National Vital Statistics System at http://wonder.cdc.gov. COPD as the underlying cause of death was defined by ICD-10 codes J40-J44. Death rates are reported per 100,000 population and were age-standardized to the 2000 U.S. standard population

==External Links==
[http://www.example.org http://www.cdc.gov/copd/data.htm]

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm cdc.gov]

==References==
{{reflist|2}}
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Mature chapter]]
[[Category:primary care]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Chronic obstructive pulmonary disease epidemiology and demographics

2014-06-12T14:02:19Z

Hilda Mahmoudi: /* Economical Impact */

__NOTOC__
{{Chronic obstructive pulmonary disease}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]
==Overview==
COPD occurs in 34 out of 1000 greater than 65 years old. In England, an estimated 842,100 of 50 million people have a diagnosis of COPD; translating into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas. In the United States, the [[prevalence]] of COPD is approximately 1 in 20 or 5%, totalling approximately 13.5 million people in USA,<ref>[http://www.wrongdiagnosis.com/c/copd/prevalence.htm wrongdiagnosis.com > Prevalence and Incidence of COPD] Retrieved on Mars 14, 2010</ref> or possibly approximately 25 million people if undiagnosed cases are included.<ref>[http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf MORBIDITY & MORTALITY: 2009 CHART BOOK ON CARDIOVASCULAR, LUNG, AND BLOOD DISEASES] National Heart, Lung, and Blood Institute</ref>

==Epidemiology and Demographics==
===Developed Countries===
====USA====

=====Mortality=====

* During 2000--2005, COPD was the underlying cause of death for 718,077 persons overall aged >25 years in the United States. The number of deaths from COPD increased from 116,494 in 2000 to 121,267 in 2003, decreased to 117,134 in 2004, and increased to 126,005 in 2005.
* To update national estimates of deaths from COPD for the period 2000-2005 (the most recent years for which data are available), CDC analyzed data from the National Vital Statistics System (NVSS). Results of that analysis indicated that an estimated 126,005 deaths of persons aged >25 years occurred in 2005 with COPD as the underlying cause, an increase of 8% from 116,494 deaths in 2000.
* In 2005, approximately one in 20 deaths in the United States had [[COPD]] as the underlying cause.
* Smoking is estimated to be responsible for at least 75% of COPD deaths.

=====Age=====

* Age-standardized COPD mortality rates remained fairly stable during the period (2000-2005) overall. Age-standardized death rates per 100,000 population decreased during 2000--2004; the rate in 2005 was similar to that for 2003.

=====Race=====

* For each year during 2000--2005, COPD mortality rates were higher among whites than among blacks or persons of all other races. During this period, the rate for blacks remained stable, except for 2004, when the rate was lower. In 2005, the death rate among white men was 80.2 (95% confidence interval [CI] = 79.5--80.9) compared with 63.8 (CI = 61.8--65.8) among black men, 60.3 (CI = 59.8--60.8) among white women, and 29.9 (CI = 28.9--30.9) among black women.

=====Gender=====

* From 2000 to 2005, the annual number of deaths from COPD increased 5% among men, and the number of deaths was higher in 2005 than in 2004. The death rate for men declined during 2000--2005 and was lower in 2004 than in 2005. Among women, the annual number of deaths increased 11% from 2000 to 2005 and was lower in 2005 than in 2004. The death rate for women increased from 2000 to 2003, decreased in 2004, and increased in 2005. The death rate was higher for men compared with the rate for women in each year, but the number of deaths was greater for women. For women, the number of deaths related to COPD in 2005 was 65,193, while for men it was 60,812.

=====Economical Impact=====

* The total economic costs of COPD in the United States were estimated to be $49.9 billion in 2010, and the total direct cost of medical care is approximately $29.5 billion per year.<ref>[A Q, J WT, E WS, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of internal medicine 2011;155:179-91]</ref> Excess health-care expenditures are estimated at nearly $6,000 annually for every COPD patient in the United States.

=====States Based Statistics=====

* By state, in 2005, age-standardized death rates from COPD for adults aged >25 years ranged from 27.1 per 100,000 in Hawaii to 93.6 per 100,000 population in Oklahoma. States with COPD death rates in the highest quartile were as follows: Idaho, Indiana, Kansas, Kentucky, Maine, Montana, Nevada, Ohio, Oklahoma, Vermont, West Virginia, and Wyoming. Among adults aged 25--64 years, rates ranged from 6.2 (Massachusetts and New Jersey) to 19.2 (Oklahoma) per 100,000 population for men and from 3.8 (New Jersey) to 16.5 (West Virginia) in women. Among adults aged >65 years, rates ranged from 169.0 (Hawaii) to 540.4 (Vermont) per 100,000 population in men and from 94.7 (Hawaii) to 394.9 (Nevada) in women.

===Statistics===
====Work Related Lung Disease (World) Surveillance System====
This CDC national surveillance system is maintained by the National Institute for Occupational Safety and Health (NIOSH) and includes up-to-date summary tables, graphs, and figures of occupationally-related respiratory disease surveillance data on the pneumoconioses, occupational asthma and other airways diseases, and several other respiratory conditions including chronic obstructive pulmonary disease. Information is available at http://www2a.cdc.gov/drds/WorldReportData/.

http://www.cdc.gov/copd/images/copd_graph.jpg

===Prevalence in the United States===

http://www.cdc.gov/copd/images/copd_map.png

Age-standardized death rates for chronic obstructive pulmonary disease (COPD), by state, aggregated over 1999–2006. State rates are grouped into quartiles. Data were obtained from the National Vital Statistics System at http://wonder.cdc.gov. COPD as the underlying cause of death was defined by ICD-10 codes J40-J44. Death rates are reported per 100,000 population and were age-standardized to the 2000 U.S. standard population

==External Links==
[http://www.example.org http://www.cdc.gov/copd/data.htm]

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm cdc.gov]

==References==
{{reflist|2}}
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Mature chapter]]
[[Category:primary care]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Chronic obstructive pulmonary disease epidemiology and demographics

2014-06-12T13:59:50Z

Hilda Mahmoudi: /* Economical Impact */

__NOTOC__
{{Chronic obstructive pulmonary disease}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]
==Overview==
COPD occurs in 34 out of 1000 greater than 65 years old. In England, an estimated 842,100 of 50 million people have a diagnosis of COPD; translating into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas. In the United States, the [[prevalence]] of COPD is approximately 1 in 20 or 5%, totalling approximately 13.5 million people in USA,<ref>[http://www.wrongdiagnosis.com/c/copd/prevalence.htm wrongdiagnosis.com > Prevalence and Incidence of COPD] Retrieved on Mars 14, 2010</ref> or possibly approximately 25 million people if undiagnosed cases are included.<ref>[http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf MORBIDITY & MORTALITY: 2009 CHART BOOK ON CARDIOVASCULAR, LUNG, AND BLOOD DISEASES] National Heart, Lung, and Blood Institute</ref>

==Epidemiology and Demographics==
===Developed Countries===
====USA====

=====Mortality=====

* During 2000--2005, COPD was the underlying cause of death for 718,077 persons overall aged >25 years in the United States. The number of deaths from COPD increased from 116,494 in 2000 to 121,267 in 2003, decreased to 117,134 in 2004, and increased to 126,005 in 2005.
* To update national estimates of deaths from COPD for the period 2000-2005 (the most recent years for which data are available), CDC analyzed data from the National Vital Statistics System (NVSS). Results of that analysis indicated that an estimated 126,005 deaths of persons aged >25 years occurred in 2005 with COPD as the underlying cause, an increase of 8% from 116,494 deaths in 2000.
* In 2005, approximately one in 20 deaths in the United States had [[COPD]] as the underlying cause.
* Smoking is estimated to be responsible for at least 75% of COPD deaths.

=====Age=====

* Age-standardized COPD mortality rates remained fairly stable during the period (2000-2005) overall. Age-standardized death rates per 100,000 population decreased during 2000--2004; the rate in 2005 was similar to that for 2003.

=====Race=====

* For each year during 2000--2005, COPD mortality rates were higher among whites than among blacks or persons of all other races. During this period, the rate for blacks remained stable, except for 2004, when the rate was lower. In 2005, the death rate among white men was 80.2 (95% confidence interval [CI] = 79.5--80.9) compared with 63.8 (CI = 61.8--65.8) among black men, 60.3 (CI = 59.8--60.8) among white women, and 29.9 (CI = 28.9--30.9) among black women.

=====Gender=====

* From 2000 to 2005, the annual number of deaths from COPD increased 5% among men, and the number of deaths was higher in 2005 than in 2004. The death rate for men declined during 2000--2005 and was lower in 2004 than in 2005. Among women, the annual number of deaths increased 11% from 2000 to 2005 and was lower in 2005 than in 2004. The death rate for women increased from 2000 to 2003, decreased in 2004, and increased in 2005. The death rate was higher for men compared with the rate for women in each year, but the number of deaths was greater for women. For women, the number of deaths related to COPD in 2005 was 65,193, while for men it was 60,812.

=====Economical Impact=====

* The total economic costs of COPD in the United States were estimated to be $49.9 billion in 2010, and the total direct cost of medical care is approximately $29.5 billion per year.<ref>[A Q, J WT, E WS, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of internal medicine 2011;155:179-91]<./ref> Excess health-care expenditures are estimated at nearly $6,000 annually for every COPD patient in the United States.

=====States Based Statistics=====

* By state, in 2005, age-standardized death rates from COPD for adults aged >25 years ranged from 27.1 per 100,000 in Hawaii to 93.6 per 100,000 population in Oklahoma. States with COPD death rates in the highest quartile were as follows: Idaho, Indiana, Kansas, Kentucky, Maine, Montana, Nevada, Ohio, Oklahoma, Vermont, West Virginia, and Wyoming. Among adults aged 25--64 years, rates ranged from 6.2 (Massachusetts and New Jersey) to 19.2 (Oklahoma) per 100,000 population for men and from 3.8 (New Jersey) to 16.5 (West Virginia) in women. Among adults aged >65 years, rates ranged from 169.0 (Hawaii) to 540.4 (Vermont) per 100,000 population in men and from 94.7 (Hawaii) to 394.9 (Nevada) in women.

===Statistics===
====Work Related Lung Disease (World) Surveillance System====
This CDC national surveillance system is maintained by the National Institute for Occupational Safety and Health (NIOSH) and includes up-to-date summary tables, graphs, and figures of occupationally-related respiratory disease surveillance data on the pneumoconioses, occupational asthma and other airways diseases, and several other respiratory conditions including chronic obstructive pulmonary disease. Information is available at http://www2a.cdc.gov/drds/WorldReportData/.

http://www.cdc.gov/copd/images/copd_graph.jpg

===Prevalence in the United States===

http://www.cdc.gov/copd/images/copd_map.png

Age-standardized death rates for chronic obstructive pulmonary disease (COPD), by state, aggregated over 1999–2006. State rates are grouped into quartiles. Data were obtained from the National Vital Statistics System at http://wonder.cdc.gov. COPD as the underlying cause of death was defined by ICD-10 codes J40-J44. Death rates are reported per 100,000 population and were age-standardized to the 2000 U.S. standard population

==External Links==
[http://www.example.org http://www.cdc.gov/copd/data.htm]

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm cdc.gov]

==References==
{{reflist|2}}
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Mature chapter]]
[[Category:primary care]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Chronic obstructive pulmonary disease epidemiology and demographics

2014-06-12T13:58:03Z

Hilda Mahmoudi: /* Economical Impact */

__NOTOC__
{{Chronic obstructive pulmonary disease}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]
==Overview==
COPD occurs in 34 out of 1000 greater than 65 years old. In England, an estimated 842,100 of 50 million people have a diagnosis of COPD; translating into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas. In the United States, the [[prevalence]] of COPD is approximately 1 in 20 or 5%, totalling approximately 13.5 million people in USA,<ref>[http://www.wrongdiagnosis.com/c/copd/prevalence.htm wrongdiagnosis.com > Prevalence and Incidence of COPD] Retrieved on Mars 14, 2010</ref> or possibly approximately 25 million people if undiagnosed cases are included.<ref>[http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf MORBIDITY & MORTALITY: 2009 CHART BOOK ON CARDIOVASCULAR, LUNG, AND BLOOD DISEASES] National Heart, Lung, and Blood Institute</ref>

==Epidemiology and Demographics==
===Developed Countries===
====USA====

=====Mortality=====

* During 2000--2005, COPD was the underlying cause of death for 718,077 persons overall aged >25 years in the United States. The number of deaths from COPD increased from 116,494 in 2000 to 121,267 in 2003, decreased to 117,134 in 2004, and increased to 126,005 in 2005.
* To update national estimates of deaths from COPD for the period 2000-2005 (the most recent years for which data are available), CDC analyzed data from the National Vital Statistics System (NVSS). Results of that analysis indicated that an estimated 126,005 deaths of persons aged >25 years occurred in 2005 with COPD as the underlying cause, an increase of 8% from 116,494 deaths in 2000.
* In 2005, approximately one in 20 deaths in the United States had [[COPD]] as the underlying cause.
* Smoking is estimated to be responsible for at least 75% of COPD deaths.

=====Age=====

* Age-standardized COPD mortality rates remained fairly stable during the period (2000-2005) overall. Age-standardized death rates per 100,000 population decreased during 2000--2004; the rate in 2005 was similar to that for 2003.

=====Race=====

* For each year during 2000--2005, COPD mortality rates were higher among whites than among blacks or persons of all other races. During this period, the rate for blacks remained stable, except for 2004, when the rate was lower. In 2005, the death rate among white men was 80.2 (95% confidence interval [CI] = 79.5--80.9) compared with 63.8 (CI = 61.8--65.8) among black men, 60.3 (CI = 59.8--60.8) among white women, and 29.9 (CI = 28.9--30.9) among black women.

=====Gender=====

* From 2000 to 2005, the annual number of deaths from COPD increased 5% among men, and the number of deaths was higher in 2005 than in 2004. The death rate for men declined during 2000--2005 and was lower in 2004 than in 2005. Among women, the annual number of deaths increased 11% from 2000 to 2005 and was lower in 2005 than in 2004. The death rate for women increased from 2000 to 2003, decreased in 2004, and increased in 2005. The death rate was higher for men compared with the rate for women in each year, but the number of deaths was greater for women. For women, the number of deaths related to COPD in 2005 was 65,193, while for men it was 60,812.

=====Economical Impact=====

* The total economic costs of COPD in the United States were estimated to be $49.9 billion in 2010, and the total direct cost of medical care is approximately $29.5 billion per year.[A Q, J WT, E WS, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of internal medicine 2011;155:179-91] Excess health-care expenditures are estimated at nearly $6,000 annually for every COPD patient in the United States.

=====States Based Statistics=====

* By state, in 2005, age-standardized death rates from COPD for adults aged >25 years ranged from 27.1 per 100,000 in Hawaii to 93.6 per 100,000 population in Oklahoma. States with COPD death rates in the highest quartile were as follows: Idaho, Indiana, Kansas, Kentucky, Maine, Montana, Nevada, Ohio, Oklahoma, Vermont, West Virginia, and Wyoming. Among adults aged 25--64 years, rates ranged from 6.2 (Massachusetts and New Jersey) to 19.2 (Oklahoma) per 100,000 population for men and from 3.8 (New Jersey) to 16.5 (West Virginia) in women. Among adults aged >65 years, rates ranged from 169.0 (Hawaii) to 540.4 (Vermont) per 100,000 population in men and from 94.7 (Hawaii) to 394.9 (Nevada) in women.

===Statistics===
====Work Related Lung Disease (World) Surveillance System====
This CDC national surveillance system is maintained by the National Institute for Occupational Safety and Health (NIOSH) and includes up-to-date summary tables, graphs, and figures of occupationally-related respiratory disease surveillance data on the pneumoconioses, occupational asthma and other airways diseases, and several other respiratory conditions including chronic obstructive pulmonary disease. Information is available at http://www2a.cdc.gov/drds/WorldReportData/.

http://www.cdc.gov/copd/images/copd_graph.jpg

===Prevalence in the United States===

http://www.cdc.gov/copd/images/copd_map.png

Age-standardized death rates for chronic obstructive pulmonary disease (COPD), by state, aggregated over 1999–2006. State rates are grouped into quartiles. Data were obtained from the National Vital Statistics System at http://wonder.cdc.gov. COPD as the underlying cause of death was defined by ICD-10 codes J40-J44. Death rates are reported per 100,000 population and were age-standardized to the 2000 U.S. standard population

==External Links==
[http://www.example.org http://www.cdc.gov/copd/data.htm]

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm cdc.gov]

==References==
{{reflist|2}}
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Mature chapter]]
[[Category:primary care]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Middle East respiratory syndrome coronavirus infection overview

2014-06-03T18:53:09Z

Hilda Mahmoudi: /* Epidemiology and Demographics */

__NOTOC__
{{MERS}}
{{CMG}}

==Overview==
[[Middle East Respiratory Syndrome]] (MERS) is a viral respiratory illness. MERS is caused by a [[coronavirus]] called “Middle East Respiratory Syndrome Coronavirus” (MERS-CoV). MERS-CoV is a beta coronavirus. It was first reported in 2012 in Saudi Arabia. MERS-CoV used to be called “novel coronavirus,” or “nCoV”. It is different from other coronaviruses that have been found in people before.

==Historical Perspective==
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported to cause human infection in September 2012. In July 2013, the [[World Health Organization]] (WHO) International Health Regulations Emergency Committee determined that [[MERS-CoV]] did not meet criteria for a "public health emergency of international concern," but was nevertheless of "serious and great concern".

==Pathophysiology==
Potential animal reservoirs and mechanism(s) of transmission of MERS-CoV to humans remain unclear. A zoonotic origin for MERS-CoV was initially suggested by high genetic similarity to bat [[coronavirus]]es , and some recent reports have described serologic data from camels and the identification of related [[virus]]es in bats. However, more epidemiologic data linking cases to infected animals are needed to determine if a particular species is a host, a source of human infection, or both.

==Differentiating Middle East Respiratory Syndrome Coronavirus Infection from Other Diseases==
The differential diagnosis of the [[middle east respiratory syndrome coronavirus]] infection include other respiratory tract infection, such as [[influenza]].

==Epidemiology and Demographics==
As of September 20, 2013, a total of 130 cases from eight countries have been reported to WHO; 58 (45%) of these cases have been fatal. All cases have been directly or indirectly linked through travel to or residence in four countries: Saudi Arabia, Qatar, Jordan, and the United Arab Emirates (UAE). Most reported cases involved severe respiratory illness requiring hospitalization.

As of May 28, 2014, globally, 636 laboratory-confirmed cases of infection with MERS-CoV have officially been reported to WHO, including 193 deaths. This global total includes all of the cases reported in this update, plus 17 laboratory confirmed cases officially reported to WHO by Saudi Arabia between 16 and 18 May, 2014.

==Risk Factors==
Traveling to endemic areas is a risk factor for the middle east respiratory syndrome coronavirus infection.

==Natural History, Complications and Prognosis==
Approximately 30% of patients infected with MERS-CoV died.

==History and Symptoms==
The symptoms of the middle east respiratory syndrome coronavirus infection include [[fever]], [[cough]], [[shortness of breath]] and gatsrointestinal symptoms.

==Physical Examination==
Persons with symptoms suspicious of the middle east respiratory syndrome coronavirus infection need medical evaluation. [[Physical examination]] by a health care provider may reveal [[fever]] or sometimes [[hypothermia|low body temperature]], an [[tachypnea|increased respiratory rate]], [[hypotension|low blood pressure]], a [[tachycardia|fast heart rate]], or a low [[oxygen saturation]], which is the amount of oxygen in the blood as indicated by either [[pulse oximetry]] or [[arterial blood gas|blood gas analysis]]. People who are struggling to breathe, who are confused, or who have [[cyanosis]] (blue-tinged skin) require immediate attention.

==Laboratory Findings==
Confirmatory laboratory testing now requires a positive [[polymerase chain reaction]] (PCR) of at least two, instead of one, specific genomic targets or a single positive target with sequencing of a second. Lab tests (PCR) for MERS-CoV are available at state health departments, CDC, and some international labs. Otherwise, MERS-CoV tests are not routinely available. There are a limited number of commercial tests available, but these are not FDA-approved. Clinical specimens should be collected, handled and tested appropriately.

==Medical Therapy==
There are no specific treatments recommended for illnesses caused by [[MERS-CoV]]. Medical care is supportive and to help relieve symptoms.

==Contact and Airborne Precautions==
Standard, contact, and airborne precautions are recommended for management of hospitalized patients with known or suspected [[MERS-CoV]] infection. In addition, ill people who are being evaluated for MERS-CoV infection and do not require hospitalization for medical reasons may be cared for and isolated in their home. Isolation at home is defined as the separation or restriction of activities of an ill person with a contagious disease from those who are well.

==Primary Prevention==
Enhancing infection prevention and control awareness and measures is critical to prevent the possible spread of MERS‐CoV in health care facilities. Health‐care facilities that provide care for patients suspected or confirmed to be infected with MERS‐CoV infection should take appropriate measures to decrease the risk of transmission of the [[virus]] from an infected patient to other patients, health‐care workers and visitors. It is not always possible to identify patients with MERS‐CoV early because some have mild or unusual symptoms. For this reason, it is important that health‐care workers apply standard precautions consistently with all patients – regardless of their diagnosis – in all work practices all the time.

==References==
{{Reflist|2}}

{{WH}}
{{WS}}
[[category:disease]]
[[Category:Infectious disease]]
[[category:virology]]
[[Category:Up-To-Date]]

PCI: classification of the lesion

2013-10-22T18:12:32Z

Hilda Mahmoudi: /* Type B1 */

__NOTOC__
{{Main|Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions}}
{{PCI}}
{{CMG}}

==Overview==
According to the Abrupt Vessel Closure - AHA Task Force Definition, as modified by Ellis et al., [[coronary artery|coronary]] [[lesion]] complexity is typed as A, B1, B2, and C.<ref>Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD,Peterson KL, Reeves TJ, Williams DO, Winters WL Jr, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486–502.</ref><ref name="Ellis-1988">{{Cite journal | last1 = Ellis | first1 = SG. | last2 = Roubin | first2 = GS. | last3 = King | first3 = SB. | last4 = Douglas | first4 = JS. | last5 = Weintraub | first5 = WS. | last6 = Thomas | first6 = RG. | last7 = Cox | first7 = WR. | title = Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. | journal = Circulation | volume = 77 | issue = 2 | pages = 372-9 | month = Feb | year = 1988 | doi = | PMID = 2962787 }}</ref><ref>Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193–1202.</ref>

==Classification of the Lesion==
===Type A===
<10mm, discrete, concentric readily accessible, <45 degree angle smooth contour, little or no [[calcification]], less than totally occluded, not [[ostium|ostial]], no major side branch involvement, absence of [[thrombus]].

===Type B1===
One of the following characteristics:
10-20mm, eccentric, moderate [[tortuosity]] of [[proximal]] segment, irregular contour, presence of any [[thrombus]] grade, moderate or heavy [[calcification]], total [[occlusion]] <3 months old, [[ostium|ostial]] [[lesion]] or bifurcation [[lesion]] requiring two [[guidewire]]s.

===Type B2===
Two or more of the following characteristics:
10-20mm, eccentric, moderate [[tortuosity]] or [[proximal]] segment, irregular contour, presence of any [[thrombus]] grade, moderate or heavy [[calcification]], total [[occlusion]] <3 months old, [[ostium|ostial]] [[lesion]] or bifurcation [[lesion]] requiring two [[guidewire]]s.

===Type C===
>20 mm [[diffuse]], excessive [[tortuosity]] of [[proximal]] segment, total [[occlusion]] >3 months old and/or bridging [[collaterals]] inability to protect major side branches, degenerated [[Saphenous vein graft|vein graft]] with friable [[lesions]].

==References==
{{Reflist|2}}

[[Category:Angiopedia]]
[[Category:Cardiology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

{{Coronary Angiography}}

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions

2013-10-22T16:37:14Z

Hilda Mahmoudi:

__NOTOC__
{{CMG}}; {{AE}} {{Rim}}; {{Hilda}}

==Overview==
The [[American College of Cardiology]]/[[American Heart Association]] ([[ACC]]/[[AHA]]) Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures developed a classification scheme to characterize the complexity of [[Coronary artery stenosis|coronary stenoses]] and the probability of success of a [[percutaneous intervention]]. This system was developed in 1988 prior to the widespread deployment of [[stent|coronary stents]].

==ACC/AHA Lesion-Specific Classification of the Primary Target Stenosis==
The lesion-specific classification was proposed by the Subcommittee on Percutaneous Transluminal Coronary Angioplasty to estimate the likelihood of a successful [[Angioplasty#Coronary angioplasty|angioplastic procedure]] (defined as one in which a ≥20% change in luminal diameter is achieved, with the final diameter [[Coronary artery stenosis|stenosis]] <50% and without the occurrence of death, [[acute myocardial infarction]], or the need for emergency [[Coronary artery bypass surgery|bypass operation]]) as well as the likelihood of developing [[abrupt closure|abrupt vessel closure]].<ref>Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD,Peterson KL, Reeves TJ, Williams DO, Winters WL Jr, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486–502.</ref>

===Type A Lesions (High Success, >85%; Low Risk)===
Type A lesions are associated with an anticipated success procedure rate of ≥85% and a low risk of [[abrupt closure]]. Type A lesions demonstrate all of the following characterisitics:
* Discreteness (<10 mm in length)
* Concentricity
* Ready accessibility
* Location in a nonangulated segment (<45°)
* Smoothness of contour
* Little or no [[Coronary artery calcification|calcification]]
* Absence of total occlusion
* Nonostial location
* Absence of major branch involvement
* Absence of [[PERFUSE thrombus grade|thrombus]]

===Type B Lesions (Moderate Success, 60 to 85%; Moderate Risk*)===
Type B lesions are associated with an anticipated success procedure rate ranging from 60 to 85% or a moderate risk of abrupt closure, or both. Type B lesions include all lesions that are neither type A nor type C and are usually identified by, but not limited to, the following characterisitics:
* Tubular shape (10 to 20 mm in length)
* Eccentricity
* Accessibility influenced by moderate tortuosity of proximal segment
* Location in a moderately angulated segment (>45°, <90°)
* Irregularity of contour
* Moderate or severe [[Coronary artery calcification|calcification]]
* Presence of [[PERFUSE thrombus grade|thrombus]]
* Ostial location
* Bifurcation lesions requiring double [[guidewire|guide wires]]
* Total occlusions <3 months old

<nowiki>*</nowiki> Although the risk of [[abrupt closure|abrupt vessel closure]] is moderate, in certain circumstances the likelihood of a major complication may be low as in dilation of total occlusions <3 months old or when abundant collateral channels supply the distal vessel.

===Type C Lesions (Low Success, <60%; High Risk)===
Type C lesions are associated with an anticipated success procedure rate of <60% or a high risk of abrupt closure, or both. Type C lesions demonstrate any of the following characterisitics:
* Diffuseness (>20 mm in length)
* Excessive tortuosity of proximal segments
* Location in an extremely angulated segment (>90°)
* Total occlusion >3 months old/ or bridging collaterals
* Inability to protect major side branches
* Degeneration of older vein grafts with friable lesions

==Modified ACC/AHA Lesion-Specific Classification of the Primary Target Stenosis==
The standard ACC/AHA classification of the primary target stenosis is prospectively modified to subdivide type B stenoses into '''B1''' (one adverse characteristic) and '''B2''' (≥two adverse characteristics) on the basis of previous studies suggesting the cumulative significance of mutiple adverse lesion characteristics.<ref name="Ellis-1988">{{Cite journal | last1 = Ellis | first1 = SG. | last2 = Roubin | first2 = GS. | last3 = King | first3 = SB. | last4 = Douglas | first4 = JS. | last5 = Weintraub | first5 = WS. | last6 = Thomas | first6 = RG. | last7 = Cox | first7 = WR. | title = Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. | journal = Circulation | volume = 77 | issue = 2 | pages = 372-9 | month = Feb | year = 1988 | doi = | PMID = 2962787 }}</ref><ref>Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193–1202.</ref>

==Pathophysiology==
Even in the modern era of stenting, the [http://perfuse.org PERFUSE study group] has shown that increasing lesion complexity is associated with impairments in both [[epicardial flow|epicardial]] and [[TIMI myocardial perfusion grade|myocardial perfusion]].<ref name="pmid15219518">{{cite journal| author=Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ et al.| title=Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. | journal=Am J Cardiol | year= 2004 | volume= 94 | issue= 1 | pages= 108-11 | pmid=15219518 | doi=10.1016/j.amjcard.2004.03.038 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15219518}}</ref>

==Natural History, Complications and Prognosis==
Increased lesion complexity is associated with a higher risk of [[cardiogenic shock]] and cardiovascular death.<ref name="pmid15219518">{{cite journal| author=Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ et al.| title=Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. | journal=Am J Cardiol | year= 2004 | volume= 94 | issue= 1 | pages= 108-11 | pmid=15219518 | doi=10.1016/j.amjcard.2004.03.038 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15219518 }} </ref>

==References==
{{Reflist|2}}

{{Coronary Angiography}}

[[Category:Angiopedia]]
[[Category:Cardiology]]

Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions

2013-10-22T16:36:28Z

Hilda Mahmoudi: /* Type C Lesions (Low Success, <60%; High Risk) */

__NOTOC__
{{CMG}}; {{AE}} {{Rim}}

==Overview==
The [[American College of Cardiology]]/[[American Heart Association]] ([[ACC]]/[[AHA]]) Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures developed a classification scheme to characterize the complexity of [[Coronary artery stenosis|coronary stenoses]] and the probability of success of a [[percutaneous intervention]]. This system was developed in 1988 prior to the widespread deployment of [[stent|coronary stents]].

==ACC/AHA Lesion-Specific Classification of the Primary Target Stenosis==
The lesion-specific classification was proposed by the Subcommittee on Percutaneous Transluminal Coronary Angioplasty to estimate the likelihood of a successful [[Angioplasty#Coronary angioplasty|angioplastic procedure]] (defined as one in which a ≥20% change in luminal diameter is achieved, with the final diameter [[Coronary artery stenosis|stenosis]] <50% and without the occurrence of death, [[acute myocardial infarction]], or the need for emergency [[Coronary artery bypass surgery|bypass operation]]) as well as the likelihood of developing [[abrupt closure|abrupt vessel closure]].<ref>Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD,Peterson KL, Reeves TJ, Williams DO, Winters WL Jr, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486–502.</ref>

===Type A Lesions (High Success, >85%; Low Risk)===
Type A lesions are associated with an anticipated success procedure rate of ≥85% and a low risk of [[abrupt closure]]. Type A lesions demonstrate all of the following characterisitics:
* Discreteness (<10 mm in length)
* Concentricity
* Ready accessibility
* Location in a nonangulated segment (<45°)
* Smoothness of contour
* Little or no [[Coronary artery calcification|calcification]]
* Absence of total occlusion
* Nonostial location
* Absence of major branch involvement
* Absence of [[PERFUSE thrombus grade|thrombus]]

===Type B Lesions (Moderate Success, 60 to 85%; Moderate Risk*)===
Type B lesions are associated with an anticipated success procedure rate ranging from 60 to 85% or a moderate risk of abrupt closure, or both. Type B lesions include all lesions that are neither type A nor type C and are usually identified by, but not limited to, the following characterisitics:
* Tubular shape (10 to 20 mm in length)
* Eccentricity
* Accessibility influenced by moderate tortuosity of proximal segment
* Location in a moderately angulated segment (>45°, <90°)
* Irregularity of contour
* Moderate or severe [[Coronary artery calcification|calcification]]
* Presence of [[PERFUSE thrombus grade|thrombus]]
* Ostial location
* Bifurcation lesions requiring double [[guidewire|guide wires]]
* Total occlusions <3 months old

<nowiki>*</nowiki> Although the risk of [[abrupt closure|abrupt vessel closure]] is moderate, in certain circumstances the likelihood of a major complication may be low as in dilation of total occlusions <3 months old or when abundant collateral channels supply the distal vessel.

===Type C Lesions (Low Success, <60%; High Risk)===
Type C lesions are associated with an anticipated success procedure rate of <60% or a high risk of abrupt closure, or both. Type C lesions demonstrate any of the following characterisitics:
* Diffuseness (>20 mm in length)
* Excessive tortuosity of proximal segments
* Location in an extremely angulated segment (>90°)
* Total occlusion >3 months old/ or bridging collaterals
* Inability to protect major side branches
* Degeneration of older vein grafts with friable lesions

==Modified ACC/AHA Lesion-Specific Classification of the Primary Target Stenosis==
The standard ACC/AHA classification of the primary target stenosis is prospectively modified to subdivide type B stenoses into '''B1''' (one adverse characteristic) and '''B2''' (≥two adverse characteristics) on the basis of previous studies suggesting the cumulative significance of mutiple adverse lesion characteristics.<ref name="Ellis-1988">{{Cite journal | last1 = Ellis | first1 = SG. | last2 = Roubin | first2 = GS. | last3 = King | first3 = SB. | last4 = Douglas | first4 = JS. | last5 = Weintraub | first5 = WS. | last6 = Thomas | first6 = RG. | last7 = Cox | first7 = WR. | title = Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. | journal = Circulation | volume = 77 | issue = 2 | pages = 372-9 | month = Feb | year = 1988 | doi = | PMID = 2962787 }}</ref><ref>Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193–1202.</ref>

==Pathophysiology==
Even in the modern era of stenting, the [http://perfuse.org PERFUSE study group] has shown that increasing lesion complexity is associated with impairments in both [[epicardial flow|epicardial]] and [[TIMI myocardial perfusion grade|myocardial perfusion]].<ref name="pmid15219518">{{cite journal| author=Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ et al.| title=Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. | journal=Am J Cardiol | year= 2004 | volume= 94 | issue= 1 | pages= 108-11 | pmid=15219518 | doi=10.1016/j.amjcard.2004.03.038 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15219518}}</ref>

==Natural History, Complications and Prognosis==
Increased lesion complexity is associated with a higher risk of [[cardiogenic shock]] and cardiovascular death.<ref name="pmid15219518">{{cite journal| author=Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ et al.| title=Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. | journal=Am J Cardiol | year= 2004 | volume= 94 | issue= 1 | pages= 108-11 | pmid=15219518 | doi=10.1016/j.amjcard.2004.03.038 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15219518 }} </ref>

==References==
{{Reflist|2}}

{{Coronary Angiography}}

[[Category:Angiopedia]]
[[Category:Cardiology]]

Coronary artery dominance

2013-10-21T19:28:34Z

Hilda Mahmoudi:

__NOTOC__
{{SI}}
{{CMG}}; {{AE}} {{Rim}}; {{Hilda}}

==Overview==
The dominance of coronary circulation is determined by the type of arteries that supply the posterior and inferior wall of the left ventricle. The artery that supplies the [[posterior descending artery]] (PDA) and the [[posterolateral artery]] (PLA) determines the coronary dominance. Approximately 60% of the general population are right-dominant, 25% are co-dominant, and 15% are left-dominant.<ref name="pmid15929526">{{cite journal |author=Kaimkhani ZA, Ali MM, Faruqi AM |title=Pattern of coronary arterial distribution and its relation to coronary artery diameter |journal=Journal of Ayub Medical College, Abbottabad : JAMC |volume=17 |issue=1 |pages=40-3 |year=2005 |pmid=15929526 |doi=}}</ref>

==Coronary Artery Dominance==
The coronary artery dominance describes how many of the three major branches supplying the posterior and inferior wall of the [[left ventricle]] from the [[right coronary artery]] (RCA) and how many arise from the [[circumflex artery]] (CX). In order to determine the anatomic dominance, the three inferior wall vessels must be specified. There are four types of coronary tree dominance: large right dominant, small right dominant, co-dominant and left dominant.

----
===Large Right Dominance===

Shown below is an image depicting a large right dominant coronary artery. A right coronary artery is said to have a "large" dominance when 3 branches arise beyond the distal bifurcation of the right coronary artery (RCA) to supply the septum and the infero-posterior walls. These 3 branches are as follows:

#The right posterior descending artery (RD or RPDA) supplies the inferior septum.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right inferior branch (RI) supplies the infero-posterior wall.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right posterior (RP) supplies the infero-posterior wall.

[[Image:Large_right_dominant_coronary_artery.png|500px|Large right dominant]]

CX= Circumflex artery; LAD=Left anterior descending artery; R4= Right posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RI= Right inferior artery ; RP= Right posterior artery; RPDA= Right posterior descending artery; RPL= Right posterolateral artery. For a full description of the labels, please see the table at bottom of the page.

----

===Small Right Dominance===

Shown below is an image depicting a small right dominant coronary artery. A right coronary artery is said to have a "small" dominance when 2 branches arise beyond the distal bifurcation of the right coronary artery to supply the septum and the posterior wall. These 2 branches are as follows:

#The right posterior descending artery (RD or RPDA) supplies the inferior septum.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right inferior branch (RI) supplies the infero-posterior wall.

The circumflex posterior artery (CP) arises from the circumflex artery (CX) and supplies the inferior wall.

[[Image:Small_right_dominant_coronary_artery.png|500px|Small right dominant]]

CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; R4= Right posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RI= Right inferior artery ; RPDA= Right posterior descending artery; RPL= Right posterolateral artery. For a full description of the labels, please see the table at bottom of the page.

----

===Co-Dominance===

Shown below is an image depicting co-dominant coronary artery. A coronary artery is said to have a "co-dominance" or balanced dominance when only the right posterior descending artery (RD or RPDA) arises from the right coronary artery (RCA), while the circumflex inferior artery (CI) and the circumflex posterior artery (CP) arise from the circumflex artery (CX).

[[Image:Co_dominant_coronary_artery.png|500px|Co-dominance]]

C4= Left posterolateral artery; CI= Circumflex inferior artery; CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; LPL= Left posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RPDA= Right posterior descending artery. For a full description of the labels, please see the table at bottom of the page.

----

===Left Dominance===

Shown below is an image depicting left dominant coronary artery. A coronary artery is said to have "left" dominance when the left posterior descending artery (CD or LPDA), the circumflex inferior artery (CI) and the circumflex posterior (CP) artery all arise from the circumflex artery (CX).

[[Image:Left_dominant_coronary_artery.png|500px|Left dominant]]

C4= Left posterolateral artery; CD= Left posterior descending artery; CI= Circumflex inferior artery ; CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; LPL= Left posterolateral artery; RCA= Right coronary artery; LPDA= Left posterior descending artery. For a full description of the labels, please see the table at bottom of the page.

----
Shown below is a table listing all the segments of the RCA and LCA in terms of corresponding numbers, labels, locations and anatomic descriptions.

{| class="wikitable sortable" style="font-size:90%"
! '''Segment number'''
! '''Segment label'''
! '''Segment location'''
! '''Segment description'''
|-
| 04 || R4 || Right posterolateral artery || This is the distal continuation of the right coronary artery after the origin of the posterior descending artery. It often has an inverted U shape as described by James and the AV nodal branch originates from this artery. It carries blood to the right posterior and right inferior arteries in large right dominant anatomy, to just the right inferior branch in small right dominant anatomy, and it is not present in left or balanced dominant systems.
|-
| 8 || RD || Right posterior descending artery ||In all but left dominant systems, this vessel runs in the posterior interventricular groove and supplies septal perforator branches. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 9 || RI || Right inferior artery || Arises from the fourth segment of the right coronary artery and supplies the inferior wall. In small right dominant anatomy, it is the distal most branch arising from the right coronary artery, while in large right dominant anatomy it arises proximal to the origin of the right posterior artery. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 10 || RP ||Right posterior artery || Distal most branch to arise from the right coronary artery, but present only in large right dominant systems. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 26|| C4||Left posterolateral artery ||In left dominant or balanced systems this is the distal continuation of the circumflex artery in the atrio-ventricular groove. It carries blood to the left posterior descending artery and circumflex inferior artery in left dominant systems and to just the circumflex inferior artery in balanced dominant systems.
|-
|27 ||CP || Circumflex posterior artery ||In all but large right dominant anatomy, this branch originates at the distal end of the third segment of the circumflex at the border of the inferior and lateral left ventricular walls where it traditionally has been called a 4th marginal branch. When present, it is one of the three longest branches supplying the inferior wall of the heart.
|-
|28||CI || Circumflex inferior artery||Arises from the fourth segment of the circumflex and supplies the inferior wall. In balanced dominant anatomy, it is the distal most branch arising from the circumflex, while in left dominant anatomy it arises proximal to the origin of the left posterior descending artery. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 29||CD || Left posterior descending artery ||In left dominant systems this is the distal continuation of the left circumflex artery which travels in the interventricular groove and supplies septal perforators at the base of the heart. This branch is the distal continuation of the circumflex after it leaves the atrio-ventricular groove in left dominant anatomy. When present, it is one of the three longest branches on the inferior wall of the heart.
|}

==Coronary Angiography of the Coronary Artery Dominance==
'''Click [[Coronary angiography coronary artery dominance|here]] for the standard angiographic views of the coronary artery dominance.'''

==References==
{{Reflist|2}}

{{Arteries of chest}}
{{Coronary Angiography}}

[[Category:Cardiovascular system]]
[[Category:Cardiac anatomy]]
[[Category:Cardiology]]
[[Category:Arteries]]
[[Category:Anatomy]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Coronary artery dominance

2013-10-21T19:27:48Z

Hilda Mahmoudi:

__NOTOC__
{{SI}}
{{CMG}}; {{AE}} {{Rim}}; {{Hilda}}

==Overview==
The dominance of coronary circulation is determined by the type of arteries that supply the posterior and inferior wall of the left ventricle. The artery that supplies the [[posterior descending artery]] (PDA) and the [[posterolateral artery]] (PLA) determines the coronary dominance. Approximately 60% of the general population are right-dominant, 25% are co-dominant, and 15% are left-dominant.<ref name="pmid15929526">{{cite journal |author=Kaimkhani ZA, Ali MM, Faruqi AM |title=Pattern of coronary arterial distribution and its relation to coronary artery diameter |journal=Journal of Ayub Medical College, Abbottabad : JAMC |volume=17 |issue=1 |pages=40-3 |year=2005 |pmid=15929526 |doi=}}</ref>

==Coronary Artery Dominance==
The coronary artery dominance describes how many of the three major branches supplying the posterior and inferior wall of the [[left ventricle]] from the [[right coronary artery]] (RCA) and how many arise from the [[circumflex artery]] (CX). In order to determine the anatomic dominance, the three inferior wall vessels must be specified. There are four types of coronary tree dominance: large right dominant, small right dominant, co-dominant and left dominant.

----
===Large Right Dominance===

Shown below is an image depicting a large right dominant coronary artery. A right coronary artery is said to have a "large" dominance when 3 branches arise beyond the distal bifurcation of the right coronary artery (RCA) to supply the septum and the infero-posterior walls. These 3 branches are as follows:

#The right posterior descending artery (RD or RPDA) supplies the inferior septum.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right inferior branch (RI) supplies the infero-posterior wall.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right posterior (RP) supplies the infero-posterior wall.

[[Image:Large_right_dominant_coronary_artery.png|500px|Large right dominant]]

CX= Circumflex artery; LAD=Left anterior descending artery; R4= Right posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RI= Right inferior artery ; RP= Right posterior artery; RPDA= Right posterior descending artery; RPL= Right posterolateral artery. For a full description of the labels, please see the table at bottom of the page.

----

===Small Right Dominance===

Shown below is an image depicting a small right dominant coronary artery. A right coronary artery is said to have a "small" dominance when 2 branches arise beyond the distal bifurcation of the right coronary artery to supply the septum and the posterior wall. These 2 branches are as follows:

#The right posterior descending artery (RD or RPDA) supplies the inferior septum.
#A branch off of the right posterolateral artery (the right posterolateral artery, RPL or R4 between the two hatched lines) called the right inferior branch (RI) supplies the infero-posterior wall.

The circumflex posterior artery (CP) arises from the circumflex artery (CX) and supplies the inferior wall.

[[Image:Small_right_dominant_coronary_artery.png|500px|Small right dominant]]

CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; R4= Right posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RI= Right inferior artery ; RPDA= Right posterior descending artery; RPL= Right posterolateral artery. For a full description of the labels, please see the table at bottom of the page.

----

===Co-Dominance===

Shown below is an image depicting co-dominant coronary artery. A coronary artery is said to have a "co-dominance" or balanced dominance when only the right posterior descending artery (RD or RPDA) arises from the right coronary artery (RCA), while the circumflex inferior artery (CI) and the circumflex posterior artery (CP) arise from the circumflex artery (CX).

[[Image:Co_dominant_coronary_artery.png|500px|Co-dominance]]

C4= Left posterolateral artery; CI= Circumflex inferior artery; CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; LPL= Left posterolateral artery; RCA= Right coronary artery; RD= Right posterior descending artery; RPDA= Right posterior descending artery. For a full description of the labels, please see the table at bottom of the page.

----

===Left Dominance===

Shown below is an image depicting left dominant coronary artery. A coronary artery is said to have "left" dominance when the left posterior descending artery (CD or LPDA), the circumflex inferior artery (CI) and the circumflex posterior (CP) artery all arise from the circumflex artery (CX).

[[Image:Left_dominant_coronary_artery.png|500px|Left dominant]]

C4= Left posterolateral artery; CD= Left posterior descending artery; CI= Circumflex inferior artery ; CP= Circumflex posterior artery; CX= Circumflex artery; LAD=Left anterior descending artery; LPL= Left posterolateral artery; RCA= Right coronary artery; LPDA= Left posterior descending artery. For a full description of the labels, please see the table at bottom of the page.

----
Shown below is a table listing all the segments of the RCA and LCA in terms of corresponding numbers, labels, locations and anatomic descriptions.

{| class="wikitable sortable" style="font-size:90%"
! '''Segment number'''
! '''Segment label'''
! '''Segment location'''
! '''Segment description'''
|-
| 04 || R4 || Right posterolateral artery || This is the distal continuation of the right coronary artery after the origin of the posterior descending artery. It often has an inverted U shape as described by James and the AV nodal branch originates from this artery. It carries blood to the right posterior and right inferior arteries in large right dominant anatomy, to just the right inferior branch in small right dominant anatomy, and it is not present in left or balanced dominant systems.| 8 || RD || Right posterior descending artery ||In all but left dominant systems, this vessel runs in the posterior interventricular groove and supplies septal perforator branches. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 9 || RI || Right inferior artery || Arises from the fourth segment of the right coronary artery and supplies the inferior wall. In small right dominant anatomy, it is the distal most branch arising from the right coronary artery, while in large right dominant anatomy it arises proximal to the origin of the right posterior artery. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 10 || RP ||Right posterior artery || Distal most branch to arise from the right coronary artery, but present only in large right dominant systems. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 26|| C4||Left posterolateral artery ||In left dominant or balanced systems this is the distal continuation of the circumflex artery in the atrio-ventricular groove. It carries blood to the left posterior descending artery and circumflex inferior artery in left dominant systems and to just the circumflex inferior artery in balanced dominant systems.
|-
|27 ||CP || Circumflex posterior artery ||In all but large right dominant anatomy, this branch originates at the distal end of the third segment of the circumflex at the border of the inferior and lateral left ventricular walls where it traditionally has been called a 4th marginal branch. When present, it is one of the three longest branches supplying the inferior wall of the heart.
|-
|28||CI || Circumflex inferior artery||Arises from the fourth segment of the circumflex and supplies the inferior wall. In balanced dominant anatomy, it is the distal most branch arising from the circumflex, while in left dominant anatomy it arises proximal to the origin of the left posterior descending artery. When present, it is one of the three longest branches on the inferior wall of the heart.
|-
| 29||CD || Left posterior descending artery ||In left dominant systems this is the distal continuation of the left circumflex artery which travels in the interventricular groove and supplies septal perforators at the base of the heart. This branch is the distal continuation of the circumflex after it leaves the atrio-ventricular groove in left dominant anatomy. When present, it is one of the three longest branches on the inferior wall of the heart.
|}

==Coronary Angiography of the Coronary Artery Dominance==
'''Click [[Coronary angiography coronary artery dominance|here]] for the standard angiographic views of the coronary artery dominance.'''

==References==
{{Reflist|2}}

{{Arteries of chest}}
{{Coronary Angiography}}

[[Category:Cardiovascular system]]
[[Category:Cardiac anatomy]]
[[Category:Cardiology]]
[[Category:Arteries]]
[[Category:Anatomy]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

TIMI myocardial perfusion grade 0.5

2013-10-16T14:38:57Z

Hilda Mahmoudi:

{{SI}}

{{CMG}};{{AE}}:{{Hilda}}

==Overview==
Minimal ground glass appearance (blush) or opacification of the myocardium in the distribution of the artery.Minimal blush is being defined as being either very small in size and/or less intense or bright that normal blush

*Intensity Range: 0.5

==Example==

==Additional Examples==

==References==

{{Coronary Angiography}}

[[Category:Angiographic Definitions]]
[[Category:Cardiology]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

TIMI myocardial perfusion grade 0.5

2013-10-16T14:36:37Z

Hilda Mahmoudi:

TIMI myocardial perfusion grade 0.5

2013-10-16T14:35:07Z

Hilda Mahmoudi: Created page with "{{SI}} {{CMG}} ==Overview== Minimal ground glass appearance (blush) or opacification of the myocardium in the distribution of the artery.Minimal blush is being defined as be..."

{{SI}}

{{CMG}}

==Overview==
Minimal ground glass appearance (blush) or opacification of the myocardium in the distribution of the artery.Minimal blush is being defined as being either very small in size and/or less intense or bright that normal blush

*Intensity Range: 0.5

Coronary angiography

2013-10-16T14:31:45Z

Hilda Mahmoudi: /* How to Assess Myocardial Perfusion */

__NOTOC__
{{CMG}}

{{SK}} coronary arteriography, cardiac arteriography, cardiac angiogram, coronary angio, coronary artery angio, coronary cath, cardiac cath

==General Principles==
* [[Coronary angiography overview|Overview]]
* [[Coronary angiography historical perspective|Historical perspective]]
* [[Coronary angiography contraindications|Contraindications]]
* [[Appropriate use criteria for revascularization|Appropriate Use Criteria for Revascularization]]
* [[Coronary angiography complications|Complications]]
* [[Coronary angiography technique|Technique]]
* Angiographic film quality

==Coronary Anatomy and Projection Angles==
===Normal Coronary Anatomy===
* [[Coronary arteries]]
* [[Left coronary artery]] | [[Left main coronary artery]] | [[Left anterior descending artery]] | [[Left circumflex artery]] | [[Ramus intermedius]]
* [[Right coronary artery]]
* [[Coronary artery dominance]]

===Coronary Anatomic Variants===
* [[Separate ostia]]
* [[Anomalous origins of the coronary arteries]]
* [[Coronary artery fistula]]

===Projection Angles===
* [[Coronary angiography standard views|Standard angiographic views]]
* [[Coronary angiography left coronary artery|Left coronary artery]]
* [[Coronary angiography right coronary artery|Right coronary artery]]

==Assessment of Perfusion==
===How to Assess Epicardial Coronary Blood Flow===
* [[TIMI flow grade]]: [[TIMI flow grade 0]] | [[TIMI flow grade 1]] | [[TIMI flow grade 2]] | [[TIMI flow grade 3]]
* [[TIMI frame count (TFC)]]
* Pulsatile flow
* Deceleration

===How to Assess Myocardial Perfusion===
*[[TIMI myocardial perfusion grade]]: [[TIMI myocardial perfusion grade 0]] | [[TIMI myocardial perfusion grade 0.5]] | [[TIMI myocardial perfusion grade 1]] | [[TIMI myocardial perfusion grade 2]] | [[TIMI myocardial perfusion grade 3]]

==Assessment of Lesion Morphology==

===Lesion Complexity===
* [[Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions|ACC-AHA characteristics of type A, B, and C coronary lesions]]

===Thrombus Grades===
* [[PERFUSE thrombus grade|TIMI thrombus grade]]: [[PERFUSE thrombus grade 0|TIMI thrombus grade 0]] | [[PERFUSE thrombus grade 1|TIMI thrombus grade 1]] | [[PERFUSE thrombus grade 2|TIMI thrombus grade 2]] | [[PERFUSE thrombus grade 3|TIMI thrombus grade 3]] | [[PERFUSE thrombus grade 4|TIMI thrombus grade 4]] | [[PERFUSE thrombus grade 5|TIMI thrombus grade 5]] | [[PERFUSE thrombus grade 6|TIMI thrombus grade 6]]

===Lesion Morphology===
* [[Coronary angiography quantitative angiography|Quantitative angiography]]
* [[Quantitative coronary angiography#Definitions of Preprocedural Lesion Morphology|Definitions of Preprocedural Lesion Morphology]]
* Irregular lesion
* Disease extent
* Arterial foreshortening
* [[Infarct related artery]] ([[Culprit lesion]])
* [[Restenosis]]
* Degenerated saphenous vein graft
* [[Collaterals]]
* [[Coronary artery ulceration]]
* [[Coronary artery aneurysm]]
* [[Coronary artery bifurcation]]
* [[Coronary artery trifurcation]]

==Vein and Arterial Bypass Graft==

==Performing Diagnostic Catheterization==
[[Risks stratification and benefits of PCI]] | [[Conscious Sedation]] | [[Preparation of the Patient for Diagnostic Catheterization]] | [[Technical Aspects of the Cardiac Catheterization Laboratory]] | [[Obtaining Venous and Arterial Access]] | [[Equipment Used in Diagnostic Cardiac Catheterizaiton]] | [[Hemodynamic Assessment in the Cardiac Catheterization Laboratory]] | [[Radiation Safety]]

===Therapeutic Catheterization===
[[Coronary angiography therapeutic procedures|Therapeutic procedures]] | [[Coronary angiography advances in catheter based physical treatments|Advances in catheter based physical treatments]]

===PCI in Specific Lesion Types===
[[PCI: classification of the lesion|Classification of the Lesion]] | [[PCI in the calcified lesion|The Calcified Lesion]] | [[PCI in the ostial lesion|The Ostial Lesion]] | [[PCI in the angulated or tortuous lesion|The Angulated or Tortuous Lesion]] | [[PCI in the bifurcation lesion|The Bifurcation Lesion]] | [[PCI in the long lesion|The Long Lesion]] | [[Myocardial bridge#PCI/Stenting|The Bridge Lesion]] | [[Coronary vasospasm#Treatment of PCI-induced Vasospasm|Vasospasm]] | [[Chronic total occlusions#PCI Techniques|The Chronic Total Occlusion]] | [[PCI in the left internal mammary artery|The Left Internal Mammary Artery]] | [[Multivessel coronary artery disease#Revascularization by Percutaneous Coronary Intervention (PCI)|Multivessel Disease]] | [[Treatment of distal anastomotic lesions#Balloon angioplasty (PTCA)|Distal Anastomotic Lesions]] | [[Left main intervention|Left Main Intervention]] | [[Management of the thrombotic lesion#Mechanical Therapy|The Thrombotic Lesion]]

===PCI Complications===
[[PCI complications: vessel perforation|Vessel Perforation]] | [[PCI complications: dissection|Dissection]] | [[PCI complications: distal embolization|Distal Embolization]] | [[PCI complications: no reflow|No-reflow]] | [[PCI complications: abrupt closure|Abrupt Closure]] | [[PCI complications: restenosis|Restenosis]] | [[PCI complications: late acquired stent malapposition|Late Acquired Stent Malapposition]] | [[PCI complications: loss of side branch|Loss of Side Branch]] | [[PCI complications: multiple complications|Multiple Complications]] | [[Coronary stent thrombosis]] | [[Slow flow]] | [[Pulsatile flow]] | [[Flow deceleration]] | [[Ectasia]] | [[Intimal flap]] | Staining

{{Coronary Angiography}}

[[Category:Cardiology]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Coronary angiography

2013-10-16T14:30:53Z

Hilda Mahmoudi: /* How to Assess Myocardial Perfusion */

__NOTOC__
{{CMG}}

{{SK}} coronary arteriography, cardiac arteriography, cardiac angiogram, coronary angio, coronary artery angio, coronary cath, cardiac cath

==General Principles==
* [[Coronary angiography overview|Overview]]
* [[Coronary angiography historical perspective|Historical perspective]]
* [[Coronary angiography contraindications|Contraindications]]
* [[Appropriate use criteria for revascularization|Appropriate Use Criteria for Revascularization]]
* [[Coronary angiography complications|Complications]]
* [[Coronary angiography technique|Technique]]
* Angiographic film quality

==Coronary Anatomy and Projection Angles==
===Normal Coronary Anatomy===
* [[Coronary arteries]]
* [[Left coronary artery]] | [[Left main coronary artery]] | [[Left anterior descending artery]] | [[Left circumflex artery]] | [[Ramus intermedius]]
* [[Right coronary artery]]
* [[Coronary artery dominance]]

===Coronary Anatomic Variants===
* [[Separate ostia]]
* [[Anomalous origins of the coronary arteries]]
* [[Coronary artery fistula]]

===Projection Angles===
* [[Coronary angiography standard views|Standard angiographic views]]
* [[Coronary angiography left coronary artery|Left coronary artery]]
* [[Coronary angiography right coronary artery|Right coronary artery]]

==Assessment of Perfusion==
===How to Assess Epicardial Coronary Blood Flow===
* [[TIMI flow grade]]: [[TIMI flow grade 0]] | [[TIMI flow grade 1]] | [[TIMI flow grade 2]] | [[TIMI flow grade 3]]
* [[TIMI frame count (TFC)]]
* Pulsatile flow
* Deceleration

===How to Assess Myocardial Perfusion===
*[[TIMI myocardial perfusion grade]]: [[TIMI myocardial perfusion grade 0]] | [[TIMI myocardial perfusion grade 0.5]]|[[TIMI myocardial perfusion grade 1]] | [[TIMI myocardial perfusion grade 2]] | [[TIMI myocardial perfusion grade 3]]

==Assessment of Lesion Morphology==

===Lesion Complexity===
* [[Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions|ACC-AHA characteristics of type A, B, and C coronary lesions]]

===Thrombus Grades===
* [[PERFUSE thrombus grade|TIMI thrombus grade]]: [[PERFUSE thrombus grade 0|TIMI thrombus grade 0]] | [[PERFUSE thrombus grade 1|TIMI thrombus grade 1]] | [[PERFUSE thrombus grade 2|TIMI thrombus grade 2]] | [[PERFUSE thrombus grade 3|TIMI thrombus grade 3]] | [[PERFUSE thrombus grade 4|TIMI thrombus grade 4]] | [[PERFUSE thrombus grade 5|TIMI thrombus grade 5]] | [[PERFUSE thrombus grade 6|TIMI thrombus grade 6]]

===Lesion Morphology===
* [[Coronary angiography quantitative angiography|Quantitative angiography]]
* [[Quantitative coronary angiography#Definitions of Preprocedural Lesion Morphology|Definitions of Preprocedural Lesion Morphology]]
* Irregular lesion
* Disease extent
* Arterial foreshortening
* [[Infarct related artery]] ([[Culprit lesion]])
* [[Restenosis]]
* Degenerated saphenous vein graft
* [[Collaterals]]
* [[Coronary artery ulceration]]
* [[Coronary artery aneurysm]]
* [[Coronary artery bifurcation]]
* [[Coronary artery trifurcation]]

==Vein and Arterial Bypass Graft==

==Performing Diagnostic Catheterization==
[[Risks stratification and benefits of PCI]] | [[Conscious Sedation]] | [[Preparation of the Patient for Diagnostic Catheterization]] | [[Technical Aspects of the Cardiac Catheterization Laboratory]] | [[Obtaining Venous and Arterial Access]] | [[Equipment Used in Diagnostic Cardiac Catheterizaiton]] | [[Hemodynamic Assessment in the Cardiac Catheterization Laboratory]] | [[Radiation Safety]]

===Therapeutic Catheterization===
[[Coronary angiography therapeutic procedures|Therapeutic procedures]] | [[Coronary angiography advances in catheter based physical treatments|Advances in catheter based physical treatments]]

===PCI in Specific Lesion Types===
[[PCI: classification of the lesion|Classification of the Lesion]] | [[PCI in the calcified lesion|The Calcified Lesion]] | [[PCI in the ostial lesion|The Ostial Lesion]] | [[PCI in the angulated or tortuous lesion|The Angulated or Tortuous Lesion]] | [[PCI in the bifurcation lesion|The Bifurcation Lesion]] | [[PCI in the long lesion|The Long Lesion]] | [[Myocardial bridge#PCI/Stenting|The Bridge Lesion]] | [[Coronary vasospasm#Treatment of PCI-induced Vasospasm|Vasospasm]] | [[Chronic total occlusions#PCI Techniques|The Chronic Total Occlusion]] | [[PCI in the left internal mammary artery|The Left Internal Mammary Artery]] | [[Multivessel coronary artery disease#Revascularization by Percutaneous Coronary Intervention (PCI)|Multivessel Disease]] | [[Treatment of distal anastomotic lesions#Balloon angioplasty (PTCA)|Distal Anastomotic Lesions]] | [[Left main intervention|Left Main Intervention]] | [[Management of the thrombotic lesion#Mechanical Therapy|The Thrombotic Lesion]]

===PCI Complications===
[[PCI complications: vessel perforation|Vessel Perforation]] | [[PCI complications: dissection|Dissection]] | [[PCI complications: distal embolization|Distal Embolization]] | [[PCI complications: no reflow|No-reflow]] | [[PCI complications: abrupt closure|Abrupt Closure]] | [[PCI complications: restenosis|Restenosis]] | [[PCI complications: late acquired stent malapposition|Late Acquired Stent Malapposition]] | [[PCI complications: loss of side branch|Loss of Side Branch]] | [[PCI complications: multiple complications|Multiple Complications]] | [[Coronary stent thrombosis]] | [[Slow flow]] | [[Pulsatile flow]] | [[Flow deceleration]] | [[Ectasia]] | [[Intimal flap]] | Staining

{{Coronary Angiography}}

[[Category:Cardiology]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Coronary angiography

2013-10-01T20:10:00Z

Hilda Mahmoudi: /* PCI Complications */

__NOTOC__
{{CMG}}

{{SK}} coronary arteriography, cardiac arteriography, cardiac angiogram, coronary angio, coronary artery angio, coronary cath, cardiac cath

==General Principles==
* [[Coronary angiography overview|Overview]]
* [[Coronary angiography historical perspective|Historical perspective]]
* [[Coronary angiography contraindications|Contraindications]]
* [[Appropriate use criteria for revascularization|Appropriate Use Criteria for Revascularization]]
* [[Coronary angiography complications|Complications]]
* [[Coronary angiography technique|Technique]]
* Angiographic film quality

==Coronary Anatomy and Projection Angles==
===Normal Coronary Anatomy===
* [[Coronary arteries]]
* [[Left coronary artery]] | [[Left main coronary artery]] | [[Left anterior descending artery]] | [[Left circumflex artery]] | [[Ramus intermedius]]
* [[Right coronary artery]]
* [[Coronary artery dominance]]

===Coronary Anatomic Variants===
* [[Separate ostia]]
* [[Anomalous origins of the coronary arteries]]
* [[Coronary artery fistula]]

===Projection Angles===
* [[Coronary angiography standard views|Standard angiographic views]]
* [[Coronary angiography left coronary artery|Left coronary artery]]
* [[Coronary angiography right coronary artery|Right coronary artery]]

==Assessment of Perfusion==
===How to Assess Epicardial Coronary Blood Flow===
* [[TIMI flow grade]]: [[TIMI flow grade 0]] | [[TIMI flow grade 1]] | [[TIMI flow grade 2]] | [[TIMI flow grade 3]]
* [[TIMI frame count (TFC)]]
* Pulsatile flow
* Deceleration

===How to Assess Myocardial Perfusion===
*[[TIMI myocardial perfusion grade]]: [[TIMI myocardial perfusion grade 0]] | [[TIMI myocardial perfusion grade 1]] | [[TIMI myocardial perfusion grade 2]] | [[TIMI myocardial perfusion grade 3]]

==Assessment of Lesion Morphology==

===Lesion Complexity===
* [[Coronary angiography ACC-AHA characteristics of type A, B, and C coronary lesions|ACC-AHA characteristics of type A, B, and C coronary lesions]]

===Thrombus Grades===
* [[PERFUSE thrombus grade|TIMI thrombus grade]]: [[PERFUSE thrombus grade 0|TIMI thrombus grade 0]] | [[PERFUSE thrombus grade 1|TIMI thrombus grade 1]] | [[PERFUSE thrombus grade 2|TIMI thrombus grade 2]] | [[PERFUSE thrombus grade 3|TIMI thrombus grade 3]] | [[PERFUSE thrombus grade 4|TIMI thrombus grade 4]] | [[PERFUSE thrombus grade 5|TIMI thrombus grade 5]] | [[PERFUSE thrombus grade 6|TIMI thrombus grade 6]]

===Lesion Morphology===
* [[Coronary angiography quantitative angiography|Quantitative angiography]]
* [[Quantitative coronary angiography#Definitions of Preprocedural Lesion Morphology|Definitions of Preprocedural Lesion Morphology]]
* Irregular lesion
* Disease extent
* Arterial foreshortening
* [[Infarct related artery]] ([[Culprit lesion]])
* [[Restenosis]]
* Degenerated saphenous vein graft
* [[Collaterals]]
* [[Coronary artery ulceration]]
* [[Coronary artery aneurysm]]
* [[Coronary artery bifurcation]]
* [[Coronary artery trifurcation]]

==Vein and Arterial Bypass Graft==

==Performing Diagnostic Catheterization==
[[Risks stratification and benefits of PCI]] | [[Conscious Sedation]] | [[Preparation of the Patient for Diagnostic Catheterization]] | [[Technical Aspects of the Cardiac Catheterization Laboratory]] | [[Obtaining Venous and Arterial Access]] | [[Equipment Used in Diagnostic Cardiac Catheterizaiton]] | [[Hemodynamic Assessment in the Cardiac Catheterization Laboratory]] | [[Radiation Safety]]

===Therapeutic Catheterization===
[[Coronary angiography therapeutic procedures|Therapeutic procedures]] | [[Coronary angiography advances in catheter based physical treatments|Advances in catheter based physical treatments]]

===PCI in Specific Lesion Types===
[[PCI: classification of the lesion|Classification of the Lesion]] | [[PCI in the calcified lesion|The Calcified Lesion]] | [[PCI in the ostial lesion|The Ostial Lesion]] | [[PCI in the angulated or tortuous lesion|The Angulated or Tortuous Lesion]] | [[PCI in the bifurcation lesion|The Bifurcation Lesion]] | [[PCI in the long lesion|The Long Lesion]] | [[Myocardial bridge#PCI/Stenting|The Bridge Lesion]] | [[Coronary vasospasm#Treatment of PCI-induced Vasospasm|Vasospasm]] | [[Chronic total occlusions#PCI Techniques|The Chronic Total Occlusion]] | [[PCI in the left internal mammary artery|The Left Internal Mammary Artery]] | [[Multivessel coronary artery disease#Revascularization by Percutaneous Coronary Intervention (PCI)|Multivessel Disease]] | [[Treatment of distal anastomotic lesions#Balloon angioplasty (PTCA)|Distal Anastomotic Lesions]] | [[Left main intervention|Left Main Intervention]] | [[Management of the thrombotic lesion#Mechanical Therapy|The Thrombotic Lesion]]

===PCI Complications===
[[PCI complications: vessel perforation|Vessel Perforation]] | [[PCI complications: dissection|Dissection]] | [[PCI complications: distal embolization|Distal Embolization]] | [[PCI complications: no reflow|No-reflow]] | [[PCI complications: abrupt closure|Abrupt Closure]] | [[PCI complications: restenosis|Restenosis]] | [[PCI complications: late acquired stent malapposition|Late Acquired Stent Malapposition]] | [[PCI complications: loss of side branch|Loss of Side Branch]] | [[PCI complications: multiple complications|Multiple Complications]] | [[Coronary stent thrombosis]] | [[Slow flow]] | [[Pulsatile flow]] | [[Flow deceleration]] | [[Ectasia]] | [[Intimal flap]] | Staining

{{Coronary Angiography}}

[[Category:Cardiology]]
[[Category:Angiopedia]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-23T15:13:21Z

Hilda Mahmoudi: /* Other trials */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed||NCT01105975||Evacetrapib||2
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed||NCT01448824||Evacetrapib||1
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib|| 1
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib||3
|-
|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
||3
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib||3
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib||1
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib||2
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib||2
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib||2
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease ([[Dal-PLAQUE Trial]])||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib||2

|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||Dalcetrapib||2
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||Dalcetrapib||2

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||Dalcetrapib||2
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||Dalcetrapib||2

|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated||NCT00267280|| Torcetrapib || 3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Completed ||NCT00134173 ||Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-23T15:12:55Z

Hilda Mahmoudi: /* CETP Inhibitors */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed||NCT01105975||Evacetrapib||2
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed||NCT01448824||Evacetrapib||1
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib|| 1
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib||3
|-
|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
||3
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib||3
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib||1
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib||2
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib||2
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib||2
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease ([[Dal-PLAQUE Trial]])||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib||2

|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||Dalcetrapib||2
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||Dalcetrapib||2

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||Dalcetrapib||2
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||Dalcetrapib||2

|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated||NCT00267280|| Torcetrapib || 3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Completed ||NCT00134173 ||Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-23T15:10:47Z

Hilda Mahmoudi: /* CETP Inhibitors */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed||NCT01105975||Evacetrapib||2
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed||NCT01448824||Evacetrapib||1
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib|| 1
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib||3
|-
|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
||3
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib||3
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib||1
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib||2
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib||2
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib||2
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease ([[Dal-PLAQUE Trial]])||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib||2

|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||Dalcetrapib||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||Dalcetrapib||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||Dalcetrapib||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||Dalcetrapib||

|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated||NCT00267280|| Torcetrapib || 3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Completed ||NCT00134173 ||Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T20:35:18Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed||NCT01105975||Evacetrapib||2
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed||NCT01448824||Evacetrapib||1
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib|| 1
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib||3
|-
|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
||3
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib||3
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib||1
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib||2
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib||2
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib||2
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease ([[Dal-PLAQUE Trial]])||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib||2
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated||NCT00267280|| Torcetrapib || 3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Completed ||NCT00134173 ||Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T20:34:13Z

Hilda Mahmoudi: /* CETP Inhibitors */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed||NCT01105975||Evacetrapib||2
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed||NCT01448824||Evacetrapib||1
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib|| 1
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib||3
|-
|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
||3
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib||3
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib||1
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib||2
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib||2
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib||2
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease ([[Dal-PLAQUE Trial]])||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib||2
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated||NCT00267280|| Torcetrapib || 3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Completed ||NCT00134173 ||Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T15:23:49Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]|| || || ||Apo A-1 Milano, ETC 216, MDCO 216||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient [[Dal-VESSEL Trial]]||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| NCT00134173 ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

2013-09-20T15:21:19Z

Hilda Mahmoudi:

__NOTOC__
{{High density lipoprotein}}

{{CMG}}; {{AE}}: {{Rim}}

{{SK}} Apo A-1 Milano, ETC 216, MDCO 216
==Objective==
*To study the effects of intravenous recombinant Apo A-1 Milano/[[phospholipid]] complexes (ETC-216) on arterial plaque burden in patients with [[acute coronary syndromes]] ([[ACS]]).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

*Previous studies conducted on mice and rabbits showed that rApo A-I Milano/phospholipid complex can mobilize cholesterol within 48 hours and reduce atherosclerosis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Timeline==
===Start Date===
November 2001
===End Date===
March 2003

==Methods==
*A 5 week, randomized, double-blinded, multicenter, parallel-treatment [[randomized control trial]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*Patients enrolled: 123 patients
*Patients randomly assigned: 57 patients

===Inclusion Criteria===
*Age: 30-75 years
*[[Angiography performed]] within 14 days following [[ACS]] event.
*At least 20% luminal diameter stenosis by visual estimated required
*[[Intravascular ultrasound]] ([[IVUS]]) done within 14 days of ACS event.
*No more than 50% luminal narrowing in a segment that is at least 30 mm in length.
* No previous [[percutaneous coronary intervention]] (PCI)
*Other [[anti-lipidemic drugs]] permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date.

===Study Arms===
*11 patients in placebo group consisting of 0.9% normal saline
*21 patients in low (15 mg/kg) dose ETC-216 group
*15 patients in high (45 mg/kg) dose ETC-216 group
The ratio of patient enrollment in the 3 groups was 1:2:2, respectively.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

IVUS was done at baseline. [[Intravenous infusion]] took place weekly for 5 consecutive weeks. Two weeks after infusion, [[IVUS]] was repeated for comparison.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

===Outcomes===
====Primary Outcome====
Change in percent [[atheroma]] volume as measured by [[IVUS]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
====Secondary Outcomes====
Assessment of [[adverse events]], quantitative angiographic changes, change in average maximal thickness or in total volume of atheroma,or atheroma volume change in most and least severely diseases 10-mm-long segments.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Results==
*10 patients were discontinued, while another 3 elected to discontinue
*2 patients were withdrawn for adverse events
*5 had IVUS that could not be analyzed

There was a significant difference in atheroma volume, mean change in total atheroma volume and thickness in the ETC-216 groups (combined) showing a 3.17% difference (p=0.02, p<0.001, p<0.001 respectively).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> This statistical significance was not seen in patients on placebo. Most regression using ETC-216 was seen in subsegments of 10 mm long that are severely diseased, in comparison to those with only mild disease (p<0.001).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

However, luminal diameter on angiography was not different when comparing follow-up to baseline or when comparing ETC-216 vs. placebo.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

Adverse events included mainly minor gastrointestinal events, [[headaches]],[[arthralgias]], and [[edema]] that were found in all 3 groups.
Two important adverse events that required withdrawal were:
*1 patient with elevated [[liver function tests]] 3 times the upper normal limit with nausea vomiting, and cholelithiasis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*1 patient with chills, rigors, rash, nausea, vomiting, and [[diaphoresis]] that occurred during infusion.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Conclusion==
Although Apo A-1 Milano infusions resulted in a decrease in plaque burden, further study is required to assess efficacy, safety and cost-effectiveness.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==References==
{{Reflist|2}}

{{Lipopedia}}
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:Clinical trials]]

MDCO 216

2013-09-20T15:20:18Z

Hilda Mahmoudi: ←Redirected page to Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

#Redirect [[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]

ETC 216

2013-09-20T15:19:58Z

Hilda Mahmoudi: ←Redirected page to Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

#Redirect [[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]

Apo A-1 Milano

2013-09-20T15:19:36Z

Hilda Mahmoudi: ←Redirected page to Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

#Redirect [[Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes]]

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

2013-09-20T15:18:36Z

Hilda Mahmoudi: Hilda Mahmoudi moved page A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) to Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

__NOTOC__
{{High density lipoprotein}}

{{CMG}}; {{AE}}: {{Rim}}

{{SK}} Apo A-1 Milano
==Objective==
*To study the effects of intravenous recombinant Apo A-1 Milano/[[phospholipid]] complexes (ETC-216) on arterial plaque burden in patients with [[acute coronary syndromes]] ([[ACS]]).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

*Previous studies conducted on mice and rabbits showed that rApo A-I Milano/phospholipid complex can mobilize cholesterol within 48 hours and reduce atherosclerosis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Timeline==
===Start Date===
November 2001
===End Date===
March 2003

==Methods==
*A 5 week, randomized, double-blinded, multicenter, parallel-treatment [[randomized control trial]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*Patients enrolled: 123 patients
*Patients randomly assigned: 57 patients

===Inclusion Criteria===
*Age: 30-75 years
*[[Angiography performed]] within 14 days following [[ACS]] event.
*At least 20% luminal diameter stenosis by visual estimated required
*[[Intravascular ultrasound]] ([[IVUS]]) done within 14 days of ACS event.
*No more than 50% luminal narrowing in a segment that is at least 30 mm in length.
* No previous [[percutaneous coronary intervention]] (PCI)
*Other [[anti-lipidemic drugs]] permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date.

===Study Arms===
*11 patients in placebo group consisting of 0.9% normal saline
*21 patients in low (15 mg/kg) dose ETC-216 group
*15 patients in high (45 mg/kg) dose ETC-216 group
The ratio of patient enrollment in the 3 groups was 1:2:2, respectively.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

IVUS was done at baseline. [[Intravenous infusion]] took place weekly for 5 consecutive weeks. Two weeks after infusion, [[IVUS]] was repeated for comparison.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

===Outcomes===
====Primary Outcome====
Change in percent [[atheroma]] volume as measured by [[IVUS]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
====Secondary Outcomes====
Assessment of [[adverse events]], quantitative angiographic changes, change in average maximal thickness or in total volume of atheroma,or atheroma volume change in most and least severely diseases 10-mm-long segments.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Results==
*10 patients were discontinued, while another 3 elected to discontinue
*2 patients were withdrawn for adverse events
*5 had IVUS that could not be analyzed

There was a significant difference in atheroma volume, mean change in total atheroma volume and thickness in the ETC-216 groups (combined) showing a 3.17% difference (p=0.02, p<0.001, p<0.001 respectively).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> This statistical significance was not seen in patients on placebo. Most regression using ETC-216 was seen in subsegments of 10 mm long that are severely diseased, in comparison to those with only mild disease (p<0.001).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

However, luminal diameter on angiography was not different when comparing follow-up to baseline or when comparing ETC-216 vs. placebo.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

Adverse events included mainly minor gastrointestinal events, [[headaches]],[[arthralgias]], and [[edema]] that were found in all 3 groups.
Two important adverse events that required withdrawal were:
*1 patient with elevated [[liver function tests]] 3 times the upper normal limit with nausea vomiting, and cholelithiasis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*1 patient with chills, rigors, rash, nausea, vomiting, and [[diaphoresis]] that occurred during infusion.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Conclusion==
Although Apo A-1 Milano infusions resulted in a decrease in plaque burden, further study is required to assess efficacy, safety and cost-effectiveness.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==References==
{{Reflist|2}}

{{Lipopedia}}
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:Clinical trials]]

High density lipoprotein complete list of trials

2013-09-20T14:39:24Z

Hilda Mahmoudi: /* CETP Inhibitors */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]]||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed||NCT00730236 ||AEGR-733 (Apo A-1 Milano)||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| NCT00134173 ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:34:13Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]]||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed||NCT00730236 ||AEGR-733 (Apo A-1 Milano)||3
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:31:57Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]]||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||Apo A-1 Milano
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:30:27Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]] (Apo A-1 Milano) ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

CSL-112 Trial - Phase 2a

2013-09-20T14:29:14Z

Hilda Mahmoudi: Hilda Mahmoudi moved page CSL-112 Trial - Phase 2a to A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

#REDIRECT [[A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients]]

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

2013-09-20T14:29:13Z

__NOTOC__
{{High density lipoprotein}}

{{CMG}}
==Official Title==
A phase 2a, multi-center, randomized, double-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of a single intravenous infusion of CSL112 in patients with stable atherothrombotic disease

==Objective==
To determine the safety, tolerability and pharmacokinetics of a single ascending dose of intravenous infusion of CSL-112 in patients with stable atherothrombotic disease.

==Sponsor==
CSL Limited
==Timeline==
{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%"
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Timeline'''
|-
| Style="width:30%"| '''Start Date'''||Style="width:70%"| February 2012
|-
| '''End Date'''||December 2012
|-
| '''Status'''||Completed
|-
|}
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT01499420.

==Study Description==

{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%"
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description'''
|-
| Style="width:30%"|'''Study Type'''|| Style="width:70%"|Interventional
|-
| '''Study Phase''' ||Phase 2
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design'''
|-
| '''Allocation'''||Randomized
|-
| '''Endpoint'''|| Safety Study
|-
| '''Interventional Model'''||Parallel Assignment
|-
| '''Masking'''||Double Blind
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details'''
|-
| '''Primary Purpose'''|| Prevention
|-
| '''Condition'''||Stable Atherothrombotic Disease
|-
| '''Intervention'''||CSL112 (Single escalating intravenous doses)
|-
| '''Study Arms'''||CSL112 (reconstituted high density lipoprotein) Placebo (single intravenous doses of normal saline 0.9%)
|-
| '''Population Size'''||45
|-
|}

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT01499420.

==Eligibility Criteria==
===Inclusion Criteria===
* Male or female aged 18 years to 80 years
* Subjects must have documented evidence of a history of atherosclerotic coronary artery disease/surgical revascularization
* Subjects on a stable medication regimen
* Body weight 50 kg or greater at screening
===Exclusion Criteria===
* Moderate/severe heart failure or renal impairment
* Uncontrolled hyperglycemia in subjects with type 1 or type 2 diabetes
* Receipt of the combination of omeprazole and clopidogrel within 1 month of randomization
* Subjects whose medical history, condition or medication regimen may interfere with the evaluation of the safety and tolerability of CSL112 (for example significantly altered electrocardiogram (ECG) waveform, hepatobiliary disease, malignancy, thrombocytopenia, etc.)
* Known hypersensitivity to the product components
==Outcomes==
===Primary Outcomes===
* Safety (Time Frame: 14 days) (Designated as safety issue: Yes)
: The frequency of study product-related adverse events
* Clinically significant elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) [Time Frame: 14 days] [Designated as safety issue: Yes]
: Number of subjects with clinically significant elevation of ALT or AST

===Secondary Outcomes===
* Pharmacokinetic profile of apolipoprotein A-I (apoA-I) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
: Plasma apoA-I concentration with and without baseline correction
* Plasma apoA-I area under the curve (AUC) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
* Plasma apoA-I Cmax [ Time Frame: 9 days ] [ Designated as safety issue: No ]
* Plasma apoA-I Tmax [ Time Frame: 9 days ] [ Designated as safety issue: No ]

==Publications==
===Results===
Pending
===Conclusion===
Pending

==References==
{{Reflist|2}}

{{Lipopedia}}
[[Category:Lipopedia]]
[[Category:HDL]]

High density lipoprotein complete list of trials

2013-09-20T14:28:23Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]] (Apo A-1 Milano) ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:27:26Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]] ]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]]||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]] (Apo A-1 Milano) ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:26:00Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers [[CSL-112 Trial - Phase 1]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]] (Apo A-1 Milano) ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

2013-09-20T14:24:52Z

Hilda Mahmoudi:

Apo A-1 Milano

2013-09-20T14:24:00Z

Hilda Mahmoudi: ←Redirected page to A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

#Redirect [[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]]

Infusion of Apo A-1 Milano

2013-09-20T14:22:53Z

Hilda Mahmoudi: Hilda Mahmoudi moved page Infusion of Apo A-1 Milano to A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

#REDIRECT [[A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)]]

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

2013-09-20T14:22:52Z

Hilda Mahmoudi: Hilda Mahmoudi moved page Infusion of Apo A-1 Milano to A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

__NOTOC__
{{High density lipoprotein}}

{{CMG}}; {{AE}}: {{Rim}}
==Objective==
*To study the effects of intravenous recombinant Apo A-1 Milano/[[phospholipid]] complexes (ETC-216) on arterial plaque burden in patients with [[acute coronary syndromes]] ([[ACS]]).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

*Previous studies conducted on mice and rabbits showed that rApo A-I Milano/phospholipid complex can mobilize cholesterol within 48 hours and reduce atherosclerosis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Timeline==
===Start Date===
November 2001
===End Date===
March 2003

==Methods==
*A 5 week, randomized, double-blinded, multicenter, parallel-treatment [[randomized control trial]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*Patients enrolled: 123 patients
*Patients randomly assigned: 57 patients

===Inclusion Criteria===
*Age: 30-75 years
*[[Angiography performed]] within 14 days following [[ACS]] event.
*At least 20% luminal diameter stenosis by visual estimated required
*[[Intravascular ultrasound]] ([[IVUS]]) done within 14 days of ACS event.
*No more than 50% luminal narrowing in a segment that is at least 30 mm in length.
* No previous [[percutaneous coronary intervention]] (PCI)
*Other [[anti-lipidemic drugs]] permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date.

===Study Arms===
*11 patients in placebo group consisting of 0.9% normal saline
*21 patients in low (15 mg/kg) dose ETC-216 group
*15 patients in high (45 mg/kg) dose ETC-216 group
The ratio of patient enrollment in the 3 groups was 1:2:2, respectively.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

IVUS was done at baseline. [[Intravenous infusion]] took place weekly for 5 consecutive weeks. Two weeks after infusion, [[IVUS]] was repeated for comparison.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

===Outcomes===
====Primary Outcome====
Change in percent [[atheroma]] volume as measured by [[IVUS]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
====Secondary Outcomes====
Assessment of [[adverse events]], quantitative angiographic changes, change in average maximal thickness or in total volume of atheroma,or atheroma volume change in most and least severely diseases 10-mm-long segments.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Results==
*10 patients were discontinued, while another 3 elected to discontinue
*2 patients were withdrawn for adverse events
*5 had IVUS that could not be analyzed

There was a significant difference in atheroma volume, mean change in total atheroma volume and thickness in the ETC-216 groups (combined) showing a 3.17% difference (p=0.02, p<0.001, p<0.001 respectively).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> This statistical significance was not seen in patients on placebo. Most regression using ETC-216 was seen in subsegments of 10 mm long that are severely diseased, in comparison to those with only mild disease (p<0.001).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

However, luminal diameter on angiography was not different when comparing follow-up to baseline or when comparing ETC-216 vs. placebo.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

Adverse events included mainly minor gastrointestinal events, [[headaches]],[[arthralgias]], and [[edema]] that were found in all 3 groups.
Two important adverse events that required withdrawal were:
*1 patient with elevated [[liver function tests]] 3 times the upper normal limit with nausea vomiting, and cholelithiasis.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>
*1 patient with chills, rigors, rash, nausea, vomiting, and [[diaphoresis]] that occurred during infusion.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==Conclusion==
Although Apo A-1 Milano infusions resulted in a decrease in plaque burden, further study is required to assess efficacy, safety and cost-effectiveness.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref>

==References==
{{Reflist|2}}

{{Lipopedia}}
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:Clinical trials]]

High density lipoprotein complete list of trials

2013-09-20T14:11:24Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers [[CSL-112 Trial - Phase 1]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148||rHDL
|-
|[[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T14:06:56Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers [[CSL-112 Trial - Phase 1]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
|Effect of rHDL on Atherosclerosis - Safety and Efficacy:[[THE ERASE TRIAL]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed||NCT00225719 ||rHDL||2
|-
|Improving Metabolism With HDL Cholesterol||A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Completed||NCT00395148
|-
|[[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:54:14Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers [[CSL-112 Trial - Phase 1]]|| An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed||NCT01499420 ||CSL112 (reconstituted HDL)||2
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:44:26Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|[[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:41:17Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)||Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01412034|| CER-001 (an ApoA-I-based HDL mimetic)||2
|-
|Exploratory Study of Plaque Regression (EXPRESS)||EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia||Completed|| NCT01515241||2
|-
[[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:32:01Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || CER-001 (an ApoA-I-based HDL mimetic)||2
|-
| [[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:30:30Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 || ||2
|-
| [[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-20T13:26:45Z

Hilda Mahmoudi: /* Reconstituted HDL Infusion */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: [[The CHI SQUARE Trial]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing||NCT01201837 ||
|-
| [[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-19T18:47:06Z

Hilda Mahmoudi: /* CETP Inhibitors */

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| [[CHI-SQUARE Study]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing|| ||
|-
| [[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|[[REVEAL Trial|REVEAL]]: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

High density lipoprotein complete list of trials

2013-09-19T18:45:17Z

Hilda Mahmoudi:

__NOTOC__
{{High density lipoprotein}}
{{CMG}}; {{AE}} {{Hilda}}
==Reconstituted HDL Infusion==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| [[CHI-SQUARE Study]] || CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome||Ongoing|| ||
|-
| [[CSL-112 Trial - Phase 1]] A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers || An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|| Completed||NCT01281774 ||CSL112 (reconstituted HDL)||1
|-
|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers||An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||Completed|| NCT01129661||CSL112 (reconstituted HDL)||1
|-
| [[CSL-112 Trial - Phase 2]] || A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease||Completed|| ||
|-
| [[ERASE Trial]] ||Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound||Completed|| ||
|-
| [[Infusion of Apo A-1 Milano]] ||A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Completed|| ||
|-
|}

==CETP Inhibitors==
{| class="wikitable sortable" style="font-size:90%"
! '''Name of the Trial'''
! '''Official Title'''
! '''Status'''
! '''ClinicalTrials.gov Identifier'''
! '''Drug name'''
! '''Trial phase'''
|-
| A Study of Evacetrapib in High-Risk Vascular Disease [[ACCELERATE Trial|(ACCELERATE)]] || Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes||Ongoing||NCT01687998||Evacetrapib||3
|-
| A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants
|| Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function

||Ongoing ||NCT01825889
||Evacetrapib ||3
|-
| A Study of Evacetrapib in Healthy Participants
|| Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects || Completed|| NCT01736254
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
||Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment ||Ongoing ||NCT01836185
||Evacetrapib ||1
|-
|A Study of Evacetrapib (LY2484595) in Healthy Participants
|| A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions || Ongoing||NCT01903434
||Evacetrapib ||1
|-
| Study of Food on Evacetrapib (LY2484595) in Healthy Participants
|| Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects ||Completed ||NCT01810432
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Rifampin in Healthy Participants
|| Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects ||Ongoing ||NCT01908582
||Evacetrapib ||1
|-
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects
|| A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects || Completed|| NCT01448824
||Evacetrapib ||1
|-
| A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects ||Completed ||NCT01825876
||Evacetrapib ||1
|-
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
|| A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C ||Completed ||NCT01105975 ||Evacetrapib ||2
|-
| A Study of Evacetrapib in Healthy Female Participants
|| Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects ||Completed || NCT01746732
||Evacetrapib ||1
|-
| A Study of Evacetrapib and Digoxin in Healthy Participants
|| Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects ||Ongoing ||NCT01897493
||Evacetrapib ||1
|-
| A Study of LY2484595 in Healthy Subjects
||Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects || Completed||NCT01450098
||Evacetrapib ||1
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed||NCT01375075||Evacetrapib||2
|-
|A Study of LY2484595 on the Electrical Activity of the Heart||A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Completed||NCT01537887
||Evacetrapib ||1
|-
|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 in Japanese Subjects||A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Completed|| ||Dalcetrapib||
|-
|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects||A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Completed|| ||Dalcetrapib||
|-
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome( [[dal-OUTCOMES Trial]])||A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Completed||NCT00658515||Dalcetrapib||3
|-
|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers||A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Completed||NCT01363999||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease ||A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)||Completed||NCT01516541||Dalcetrapib

|-

|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease||A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Completed||NCT01059682||Dalcetrapib
|-
|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) ||A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Completed||NCT01323153||Dalcetrapib
|-
|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers||An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Completed||NCT01476267||Dalcetrapib
|-
|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Completed||NCT00353522||Dalcetrapib
|-
|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient||A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents||Completed||NCT00655538||Dalcetrapib
|-
|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 ||A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Completed||NCT00400439||Dalcetrapib
|-
|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease||A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors ||Completed||NCT00655473||Dalcetrapib
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) ([[DEFINE Trial]])||A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease||Ongoing||NCT00685776||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01717300||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)||A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia||Ongoing||NCT01760460||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)||A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Completed||NCT01114490||Anacetrapib||1
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)||A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|| Ongoing||NCT01824238||Anacetrapib||3
|-
|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)||A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Completed||NCT01122667||Anacetrapib||1
|-
|REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease||Ongoing||NCT01252953||Anacetrapib||3
|-
|Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2)||A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)||Ongoing||NCT01841684||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)||A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C||Ongoing||NCT01860729||Anacetrapib||3
|-
|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE)||A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia||Ongoing||NCT01524289||Anacetrapib||3
|-
|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED)||A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Completed||NCT00977288||Anacetrapib||2
|-
|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)||A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Completed||NCT00990808||Anacetrapib||1
|-
|MK0859 Dose-Ranging Study (0859-003||MK0859 Dose-Ranging Study||Terminated||NCT00325455||Anacetrapib||2
|-
|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|| ||Completed||NCT00565292||Anacetrapib||1
|-
| [[REVEAL Trial]] ||
|-
|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease [[ILLUMINATE Trial|(ILLUMINATE)]]||Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents||Terminated||NCT00134264|| Torcetrapib||3
|-
| Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia || Completed ||NCT00139061
|| Torcetrapib ||3
|-
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|| Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia || Completed ||NCT00134511
|| Torcetrapib ||3
|-
|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia || Completed ||NCT00134485 || Torcetrapib ||3
|-
|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder||Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) || Terminated ||NCT00145431
|| Torcetrapib || 3
|-
| A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides || Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia || Completed || NCT00134498|| Torcetrapib||3
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol || A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030) || Completed ||NCT00267254|| Torcetrapib ||3
|-
| A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|| Completed ||NCT00138762|| Torcetrapib ||3
|-
|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031). ||A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031) || Terminated ||NCT00267280
|| Torcetrapib ||
|-
| A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|| Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia ||Terminated ||NCT00267267
|| Torcetrapib||3
|-
| Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia || Terminated || NCT00134238
|| Torcetrapib||3
|-
| A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease [[ILLUSTRATE Trial|(ILLUSTRATE)]] || Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

|| Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease. ||Completed || Torcetrapib|| 3
|-
| Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
|| An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials. || Terminated ||NCT00452842|| Torcetrapib|| Observational
|-
| Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
||A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias || Completed || NCT00137462
|| Torcetrapib||3
|-
| Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. (RADIANCE 1)
|| Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.||Completed || NCT00136981|| Torcetrapib|| 3
|-

|}

==Niacin==
{| style="font-size:120%"
|-
| [[AIM-HIGH Trial]]
|-
| [[ARBITER 2 Trial]]
|-
| [[ARBITER 3 Trial]]
|-
| [[ARBITER 6-HALTS Trial]]
|-
| [[CLAS Trial]]
|-
| [[HATS Trial]]
|-
| [[Oxford Niaspan Study]]
|-
|}

==Fibrate==
{| style="font-size:120%"
|-
| [[VA-HIT Trial]]
|-
| [[BECAIT Trial]]
|-
| [[BIP Trial]]
|-
|}

==Statin==
{| style="font-size:120%"
|-
| [[ASTEROID Trial]]
|-
| [[SATURN Trial]]
|-
| [[4S Trial]]
|-
| [[CORONA Trial]]
|-
|}

==Multiple Lipid Lowering Drugs==
{| style="font-size:120%"
|-
| [[HARP Study]]
|-
| [[AFREGS Trial]]
|-
|}

==Other trials==
{| style="font-size:120%" border="1"
|-
| '''Name of the Trial'''|| '''Official Name'''||'''Status'''||'''ClinicalTrials.gov Identifier'''||
|-
|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||completed||NCT00688896||
|-
|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Completed||NCT00686010||

|-

|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Completed||NCT00689442||
|-
|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels||A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||completed||NCT00688558||

|}

{{Lipopedia}}

[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}